A randomized, open-label study of the tolerability and efficacy of one or three daily doses of ivermectin plus diethylcarbamazine and albendazole (IDA) versus one dose of ivermectin plus albendazole (IA) for treatment of onchocerciasis

Nicholas O. Opoku, Felix Doe, Bettina Dubben, Nicole Fetcho, Kerstin Fischer, Peter U. Fischer, Shelter Gordor, Charles W. Goss, Michael E. Gyasi, Achim Hoerauf, Augustine Hong, Eric Kanza, Christopher L. King, Ruth Laryea, Daphne Lew, Mahmood A. Seidu, Gary J. Weil

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Fingerprint

Dive into the research topics of 'A randomized, open-label study of the tolerability and efficacy of one or three daily doses of ivermectin plus diethylcarbamazine and albendazole (IDA) versus one dose of ivermectin plus albendazole (IA) for treatment of onchocerciasis'. Together they form a unique fingerprint.

Medicine & Life Sciences

Social Sciences